do not combine dpp-4 inhibitors with glp-1 receptor agonists guideline 𝐋𝐚𝐭𝐞𝐬𝐭 𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧 𝐨𝐟 𝐃𝐏𝐏-𝟒 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫𝐬 (𝐞.𝐠., 𝐬𝐢𝐭𝐚𝐠𝐥𝐢𝐩𝐭𝐢𝐧, 𝐬𝐚𝐱𝐚𝐠𝐥𝐢𝐩𝐭𝐢𝐧, 𝐥𝐢𝐧𝐚𝐠𝐥𝐢𝐩𝐭𝐢𝐧, 𝐚𝐥𝐨𝐠𝐥𝐢𝐩𝐭𝐢𝐧, 𝐯𝐢𝐥𝐝𝐚𝐠𝐥𝐢𝐩𝐭𝐢𝐧) 𝐢𝐧 𝐭𝐡𝐞 𝟐𝟎𝟐𝟓 𝐀𝐃𝐀 𝐒𝐭𝐚𝐧𝐝𝐚𝐫𝐝𝐬 𝐨𝐟 Major adverse cardiovascular and limb

:INH000017338, IN/AIF3/24-25/1571, IN/AIF2/24-25/1607 | BASL Membership ID: 6276 Investment in Securities Market are subject to market risks

This is melting fat fast, even stubborn areas are shrinking

Common adverse effects include nausea and vomiting, as well as increased hazards of gastroparesis and small bowel obstruction

Higher amounts do not necessarily yield faster results due to saturation points in cellular receptors

For example, HCPs should discuss the importance of balanced nutritional intake with all patients prescribed GLP-1 RAs, alongside monitoring signs of malnutrition, micronutrient status, and changes in body composition

This is why many athletes and bodybuilders stick to a program containing peptides